Navigation Links
Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
Date:1/14/2014

Panama City, Panama (PRWEB) January 14, 2014

Translational Biosciences, a subsidiary of Medistem Panama has received the county’s first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comité Nacional de Bioética de la Investigación Institutional Review Board (IRB).

Rheumatoid Arthritis (RA) is an autoimmune disease in which the patient’s immune system generates cellular and antibody responses to various components of the joint such as type I collagen. As a result of this immune response, not only does joint destruction occur, but also other secondary complications such as pulmonary fibrosis, renal damage, and even heart damage. RA affects approximately 0.5-1% of the population in the United States.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve RA symptoms. Because they are immune privileged, the recipient’s immune system does not reject them. These properties make MSC interesting candidates for the treatment of rheumatoid arthritis and other autoimmune disorders.

Each patient will receive five intravenous injections of umbilical cord stem cells over the course of 5 days. They will be assessed at 3 months and 12 month primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panama’s 8000 sq. ft. laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

“While this i
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ceres Announces Fiscal First Quarter 2014 Financial Results
2. Louisiana’s First Clinical Data Research Network to Be Developed Through PCORI Funding
3. First Implantation of New Intrathecal Drug Pump to Treat Chronic Pain
4. Grace Century Attends Provia Labs First Quarter Expansion Meeting January 5-10
5. Texas Childrens Hospital named first Accredited Pediatric Heart Failure Institute in Texas
6. York U molecular communication researchers send worlds first text message using vodka
7. Remedy Informatics to Partner with Nemours Center for Cancer and Blood Disorders on Development of First-Ever Pediatric Oncology Registry
8. ThoroughGen Creates First Genetic Breeding Model for Thoroughbreds
9. Cells from the eye are inkjet printed for the first time
10. ASEA, LLC. to Expand Product Shipments to Mexico in First Quarter 2014
11. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... ... 30, 2015 , ... Park Systems , world-leader in ... into new classes of Nanoscale Graphene-based materials poised to revolutionize industries such as ... of the 21st Century' by the researchers who were awarded the 2010 Nobel ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
... Jan. 6, 2011 Vista Partners announced today ... (Nasdaq: OPXA ) and raised its twelve ... Analyst at Vista Partners stated, "Opexa announced yesterday that their ... treatment of Multiple sclerosis , is now positioned from ...
... 2011 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical ... focusing on the early diagnosis and preventive treatment of ... two U.S. events: the 28th J.P. Morgan Healthcare Conference ... Showcase (from January 10th to 12th, 2011). ...
Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
(Date:7/2/2015)... Fingerprint Cards has received an order ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... by smartphone manufacturers in Asia . The ... revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... British Columbia researchers have identified a small virus that ... size, rescuing the infected zooplankton from certain death. The ... jumping genes found in other organisms. The study, ... Matthias Fischer, is published online today in Science Express. ...
... at managing environmental impacts of agriculture have spurred ... and natural fertilizers for commercial applications. Many organic ... other processing industries. In Mississippi, where the poultry ... each year, and annual chicken litter production is ...
... New University of Georgia research has identified a protein ... of the most common drugs used to treat pancreatic cancer. ... journal Cancer Research, found that a cell-surface protein ... reduced in function in two thirds of pancreatic tumors. By ...
Cached Biology News:'David and Goliath' viruses shed light on the origin of jumping genes: UBC study 2Chicken litter provides organic alternative to synthetic fertilizers 2Researchers find possible new treatment strategies for pancreatic cancer 2
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Biology Products: